<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336218</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00015</org_study_id>
    <nct_id>NCT01336218</nct_id>
  </id_info>
  <brief_title>Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.</brief_title>
  <official_title>An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the drug interaction between fostamatinib and
      rifampicin by comparing the safety, tolerability and plasma concentration of fostamatinib
      when administered alone and with rifampicin in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetics of R406 in healthy subjects when a single dose of fostamatinib is administered alone and in combination with rifampicin. AUC and Cmax will be measured</measure>
    <time_frame>Period 1: Day 1 to 96 hours post-dose Period 2: Day 6 to 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics of R406 in healthy subjects when a single dose of fostamatinib is administered alone and in combination with rifampicin. AUC (0-t), terminal half life, and tmax will be measured</measure>
    <time_frame>Period 1: Day 1 to 96 hours post-dose Period 2: Day 6 to 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of fostamatinib in combination with rifampicin.</measure>
    <time_frame>From screening, Day 1 - Day 25, up to follow up visit</time_frame>
    <description>Assessments include: Adverse events, laboratory assessments, vital signs, physical examination and 12-lead electrocardiogram. Absolute values and change in baseline for any of these parameters will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fostamatinib</intervention_name>
    <description>oral tablets, 150mg (3 X 50mg) single dose per period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampicin</intervention_name>
    <description>oral tablets, 600mg (2 X 300mg) 8 doses over 8 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Males or females aged 18 to 55 years (inclusive)

          -  Minimum weight of 50 kg and a body mass index (BMI) of 18 to 35 kg/m2 (inclusive)

          -  Female subjects must have a negative pregnancy test at screening and admission of each
             treatment period, must not be lactating, and must be of non-childbearing potential

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic or renal disease (except for
             cholecystectomy)

          -  Any clinically significant illness, medical or surgical procedure, or trauma within 4
             weeks before Period 1 Day 1

          -  Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day

          -  Absolute neutrophil count of less than 2500/mm3 or 2.5 x 109/L

          -  Any previous treatment with fostamatinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kelli Craven, MD, PI</name_title>
    <organization>Quintiles, Overland Park, volunteer recruitment</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>Fostamatinib</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Amount of Rifampicin in blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

